Adaptive Biotechnologies Corp(ADPT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:12 PM ET (Korea 10/31 05:12)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.41 | Insider Own | 2.96% | Shs Outstand | 159.1M | Perf Week | 4.43% |
| Market Cap | 4.25B | Forward P/E | - | EPS next Y | 67.99% | Insider Trans | -35.87% | Shs Float | 154.9M | Perf Month | -2.67% |
| Enterprise Value | 4.33B | PEG | - | EPS next Q | -0.09 | Inst Own | 97.54% | Short Float | 7.74% | Perf Quarter | 15.27% |
| Income | -0.06B | P/S | 13.8 | EPS this Y | -38.37% | Inst Trans | 2.31% | Short Ratio | 5.45 | Perf Half Y | 86.69% |
| Sales | 0.31B | P/B | 29.65 | EPS next 5Y | - | ROA | -11.23% | Short Interest | 11.99M | Perf YTD | 64.04% |
| Book/sh | 0.9 | P/C | 12.35 | EPS past 3/5Y | 34.64% 18.85% | ROE | -39.58% | 52W High | -13.34% ($30.74) | Perf Year | 57.54% |
| Cash/sh | 2.16 | P/FCF | - | Sales past 3/5Y | 14.34% 23% | ROIC | -11.73% | 52W Low | 122% ($12.00) | Perf 3Y | 515.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 50.4% | Gross Margin | 72.71% | Volatility(W/M) | 5.77% 6% | Perf 5Y | -20.26% |
| Dividend TTM | - | EV/Sales | 14.04 | Sales Y/Y TTM | 50.13% | Oper. Margin | -11.81% | ATR (14) | 1.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.68 | EPS Q/Q | -47.8% | Profit Margin | -20.73% | RSI (14) | 51.25 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.79 | Sales Q/Q | 21.53% | SMA20 | 1.99% ($26.12) | Beta | 2.17 | Target Price | $30.21 |
| Payout | - | Debt/Eq | 2.87 | Earnings | 2026/11/4 | SMA50 | 0.99% ($26.38) | Rel Volume | 1.97 | Prev Close | $28.17 |
| Employees | 624 | LT Debt/Eq | 2.81 | EPS/Sales Surpr. | -87.13% 9.35% | SMA200 | 35.9% ($19.6) | Avg Volume(3M) | 2.20M | Price | $26.64 |
| IPO | 2019/6/27 | Option/Short | Yes/Yes | Trades | 15902 | Volume | 4,327,259 | Change | -5.43% |
🧬 This is a US diagnostics company that develops immune-based diagnostics. It develops and provides minimal residual disease (MRD) diagnostics and immune medicine solutions using immune sequencing technology, giving it exposure to diagnostic test demand and commercialization. It is a company in the immune-based diagnostics space.
Over the past 1 year, on the higher side
13% below its 1-year high.
Traded more than usual. That is 197% of its average volume.
Next earnings report: November 4
4 days to go.
ADPT has a sound balance sheet but weak earning power
Of every $100 in sales, $11.81 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -38.4% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,380. Peers typically go for $448.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -20.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 97.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #23 of 44 in the industry
Based on market cap of $4B.
BLLN#20 Billiontoone Inc $5B PER 183.9 
SHC#21 Sotera Health Co $5B PER 31.9 
CDNA#22 Caredx Inc $5B PER 36.5 ADPT#23 Adaptive Biotechnologies Corp $4B PER - 
VCYT#24 Veracyte Inc $4B PER 35.5 
FAQ
What kind of company is ADPT?
ADPT belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of ADPT?
The market cap of ADPT is approximately $4.3B, ranking 1,488 within its sector.
What is the 52-week high and low for ADPT?
ADPT has recorded a 52-week high of $30.74 and a low of $12.00.
